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May 6th, 2018
Lentiviral vectors (LV) are used for gene and cell therapy 
2
• HIV-based, enveloped virus
• Fragile, sensitive to pH and 
temperature
• Stable gene integration into genome 
of dividing and non-dividng cells
 Gene therapy, CAR-T
80-120nm
ss RNA VSV-G
Bioprocessing of Lentiviral vectors (LV) 
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• Currently, LV are mainly produced in adherent cells by transfection of 4 plasmids: 
Virus accessory genes (Gag/Pol, Rev and VSV-G) and the gene of interest. 
Issue with
scalability
Objective: PD for stable 
producer cell lines (production 
of LV under the control of two
switches) in suspension Process
development


































Total Yield with different modes of 
operation
10-fold yield increase when operating in 
perfusion mode (sequential harvests):
Manceur et al, Human gene Therapy, 2017














































Perfusion with an ATF filter (0.5µm - PES)
2 log 
decrease
 No sequential harvesting with ATF






1. Transfer to GMP
2. Cost analysis/optimization/LV stability
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